Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
Press Releases
Ascletis Pharma Inc.  
November 12, 2024

Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne

-Phase III trial enrolled a total of 480 patients with moderate to severe acne

logo salamanca press

Salamanca Press

Local & Social